Daily Cosmetic Research Analysis
Analyzed 41 papers and selected 3 impactful papers.
Summary
Three high-impact studies span mechanistic dermatology and aesthetic surgery. A mechanistic paper reveals an exosome–histone lactylation–ferroptosis axis driving photoaging, highlighting LDHA/ACSL4 as targets. A meta-analysis clarifies trade-offs between excision and lasers for melanocytic nevi, while a systematic review exposes profound outcome-reporting heterogeneity in minimally invasive facial rejuvenation and calls for a core outcome set.
Research Themes
- Exosome-mediated epigenetic regulation and ferroptosis in skin photoaging
- Comparative effectiveness of cosmetic treatments for melanocytic nevi
- Outcome standardization in minimally invasive aesthetic trials
Selected Articles
1. Role of LDHA in senescent fibroblast exosomes promoting ferroptosis via histone lactylation-mediated ACSL4 regulation in skin photoaging.
Senescent fibroblast-derived exosomes deliver LDHA to recipient keratinocytes, elevating lactate and H3K18 lactylation at the ACSL4 promoter to drive ferroptosis and photoaging. Genetic and pharmacologic LDHA inhibition suppressed ACSL4 and ferroptosis, with partial rescue by exogenous lactate; in vivo UVB models confirmed mitigation of collagen loss with LDHA intervention.
Impact: This work uncovers a mechanistic exosome–epigenetic–ferroptosis axis linking LDHA to photoaging, identifying actionable targets (LDHA, histone lactylation, ACSL4) for anti-photoaging strategies.
Clinical Implications: Although preclinical, the LDHA–lactylation–ACSL4 axis suggests testable interventions (e.g., topical LDHA inhibitors, ferroptosis blockers, exosome modulation) for photoaging; safety and efficacy require clinical evaluation.
Key Findings
- UVB induced fibroblast senescence with marked LDHA upregulation; senescent exosomes were internalized by HaCaT cells, increasing lactate and H3K18 lactylation.
- LDHA knockdown/inhibition reduced ACSL4 expression and ferroptosis, while exogenous lactate partially rescued these effects.
- ChIP-qPCR showed enrichment of H3K18 lactylation at the ACSL4 promoter, enhancing transcription.
- In vivo UVB models demonstrated that senescent exosomes accelerated collagen degradation and ferroptosis; LDHA intervention alleviated photoaging damage.
Methodological Strengths
- Multi-system mechanistic validation (RNA-seq, ChIP-qPCR, NTA/TEM, genetic and pharmacologic perturbations)
- Concordant in vitro and in vivo evidence supporting causality
Limitations
- No human clinical validation or biomarker correlation
- Focus on fibroblast-to-keratinocyte axis; other skin cell interactions were not assessed
Future Directions: Evaluate topical/systemic LDHA inhibitors or anti-lactylation strategies in human skin models and early-phase trials; map cell type–specific lactylation and ferroptosis in human photoaged skin.
OBJECTIVE: This study aimed to elucidate the mechanism of Lactate Dehydrogenase A (LDHA) in senescent fibroblast-derived exosomes during skin photoaging, focusing on the molecular pathway by which it regulates Acyl-CoA Synthetase Long-Chain Family Member 4 (ACSL4) expression through histone lactylation, thereby inducing ferroptosis and accelerating skin photoaging. METHODS: An ultraviolet B (UVB)-induced senescence model was established using human foreskin fibroblasts. Exosomes were isolated from senescent fibroblasts and characterized. Their features and uptake were assessed using Western blot, transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), and immunofluorescence. Small interfering RNA was employed to knock down LDHA and ACSL4 gene. Pharmacological inhibitors (FX11, Ferrostatin-1) and sodium lactate rescue experiments were utilized. Lactate levels, histone H3K18 lactylation modification, ACSL4 transcriptional activity, and ferroptosis markers were detected to assess the effects of ACSL4 gene lactylation on ferroptosis. The biological effects of exosomal LDHA in photoaged tissue were validated using an in vivo UVB-irradiated mouse model. RESULTS: UVB irradiation induced fibroblast senescence and significantly upregulated LDHA expression. Exosomes from senescent fibroblasts were effectively taken up by HaCaT cells, leading to increased lactate levels and enhanced histone H3K18 lactylation in recipient cells. LDHA knockdown or inhibition downregulated ACSL4 expression and suppressed ferroptosis, whereas exogenous lactate partially restored these effects. RNA sequencing and ChIP-qPCR results indicated that LDHA-mediated lactylation modification was enriched at the ACSL4 promoter region, enhancing its transcriptional activity. In vivo experiments further confirmed that senescent exosomes accelerated UVB-induced skin collagen degradation and ferroptosis, while LDHA intervention significantly alleviated photoaging damage. CONCLUSION: Senescent fibroblast-derived exosomes deliver LDHA, promoting histone lactylation modification, which upregulates ACSL4 expression and activates the ferroptosis pathway, ultimately accelerating skin photoaging. This study reveals the coupling mechanism between metabolic signaling and epigenetic regulation in skin aging, providing new molecular targets and a theoretical basis for anti-photoaging therapy.
2. Aesthetic techniques for melanocytic nevus management: clinical outcomes, cosmetic satisfaction, and safety-a systematic review and meta-analysis.
Across 46 studies (4,201 lesions), surgical excision provided the highest clinical clearance (96.4%) with the lowest recurrence (2.1%). Laser modalities, especially Er:YAG (highest satisfaction) and CO2, yielded superior cosmetic satisfaction. Subgroup analyses by nevus subtype and modality and formal risk-of-bias assessment strengthen conclusions.
Impact: Provides quantifiable trade-offs between clearance/recurrence and cosmetic satisfaction across modalities, directly informing shared decision-making and procedural selection.
Clinical Implications: Prefer excision when complete removal and histopathology are priorities; consider Er:YAG or CO2 lasers when cosmetic outcome is paramount and histology is not required, counseling patients on recurrence risk.
Key Findings
- Surgical excision achieved the highest clinical clearance (96.4%) and the lowest recurrence (2.1%).
- Er:YAG laser produced the highest cosmetic satisfaction, followed by CO2 lasers.
- Random-effects meta-analysis with PRISMA 2020 methodology and RoB2/NOS bias assessment; subgroup analyses by nevus subtype and modality.
Methodological Strengths
- PRISMA 2020–guided systematic search with random-effects meta-analysis
- Formal risk-of-bias assessment (RoB2 for RCTs; NOS for observational studies) and prespecified subgroup analyses
Limitations
- Heterogeneity in study designs, outcome measures, and follow-up intervals across included studies
- Mixture of randomized and observational data may confound pooled estimates despite bias adjustment
Future Directions: Standardize outcome definitions (clearance, recurrence, cosmetic scales) and conduct head-to-head randomized trials stratified by nevus subtype.
BACKGROUND: Melanocytic nevi are among the most frequently treated lesions in aesthetic dermatology. Various techniques are used for cosmetic or diagnostic purposes. However, comparative evidence regarding treatment efficacy, recurrence risk, cosmetic outcomes, and safety remains inconsistent. OBJECTIVE: To systematically evaluate and compare clinical clearance, recurrence rates, cosmetic outcomes, and adverse events associated with aesthetic techniques used for the removal of melanocytic nevi. METHODS: A systematic search of PubMed, Scopus, Web of Science, ScienceDirect, Wiley, and Google Scholar was conducted for studies published between January 2000 and May 2025. Studies reporting outcomes of surgical or aesthetic interventions for benign melanocytic nevi were included. Data extraction followed PRISMA 2020 guidelines. A random-effects meta-analysis was performed to pool estimates of clinical clearance, recurrence, and cosmetic satisfaction. Subgroup analyses were conducted according to nevus subtype (junctional vs. intradermal) and treatment modality. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool for randomized trials and the Newcastle-Ottawa Scale for observational studies. RESULTS: A total of 46 studies involving 4,201 lesions were included. Surgical excision demonstrated the highest clinical clearance rate (96.4%; 95% CI 92.1-99.2) and the lowest recurrence rate (2.1%). Laser-based treatments produced the most favorable cosmetic outcomes, with Er:YAG laser achieving the highest satisfaction score (8.8/10), followed by CO CONCLUSION: Surgical excision remains the most reliable method for complete melanocytic nevus removal and histopathologic assessment but may yield less favorable cosmetic outcomes. Laser-based treatments, particularly Er:YAG and CO
3. Heterogeneity in Clinical Outcomes Reporting in Minimally-Invasive Facial Rejuvenation: Is It Time for a Core Outcomes Set?
In 242 RCTs of minimally invasive facial/neck rejuvenation, investigators used 79 clinician scales, 69 PRO scales, and 53 objective metrics; no single clinician or PRO scale appeared in over 40% of trials. Marked heterogeneity persisted even within the same modality and facial region, varying by geography and funding, underscoring the need for a core outcome set.
Impact: By quantifying outcome-reporting heterogeneity across recent RCTs, this review provides an empirical basis and urgent rationale for developing a core outcome set in aesthetic rejuvenation trials.
Clinical Implications: Until a core outcome set is established, clinicians and trialists should prioritize validated PROs and objective measures, predefine primary endpoints, and harmonize metrics across studies to enable meaningful comparisons.
Key Findings
- Across 242 RCTs, 79 clinician scales, 69 patient-reported outcome scales, and 53 objective outcomes were identified.
- No clinician- or patient-reported measure appeared in more than 40% of trials.
- Outcome definitions varied substantially even within the same modality and facial region, with differences by region and funding source.
- The authors call for a core outcome set to standardize reporting in aesthetic rejuvenation trials.
Methodological Strengths
- Comprehensive mapping of clinician, PRO, and objective outcomes across a large corpus of recent RCTs
- Focus on minimally invasive modalities with contemporary (2020–2025) evidence base
Limitations
- Descriptive synthesis without consensus development or formal evaluation of measurement properties
- Time-limited window (2020–2025) may omit earlier scales or trends
Future Directions: Convene multi-stakeholder Delphi processes to define a core outcome set spanning clinician ratings, PROs, and objective metrics; validate cross-cultural applicability and minimal clinically important differences.
INTRODUCTION: Outcome measurement in aesthetic medicine is complicated by subjective definitions of beauty, psychosocial factors, and a lack of standardized assessment metrics. Outcome reporting heterogeneity limits physicians' ability to synthesize results from multiple studies. The purpose of this study was to identify the outcomes and outcome scales used in minimally-invasive facial rejuvenation clinical trials to determine the degree of outcome heterogeneity. METHODS: A systematic review was conducted to identify all randomized control trials published in 2020-2025 focusing on non-operative or minimally-invasive facial and neck rejuvenation treatments. We identified outcome measurements reported in each study, including investigator assessment scales, patient-reported outcome scales, and objective outcomes and metrics. RESULTS: Our search identified 242 articles for inclusion. From these, we identified 79 investigator assessment scales, 69 patient-reported outcome scales, and 53 objective outcomes reported. No investigator-reported or patient-reported outcome was used in greater than 40% of trials, and within studies comparing the same treatment type applied to the same facial region, there existed substantial heterogeneity in definitions of treatment efficacy. Furthermore, differences in reported measures existed between regions and funding sources. CONCLUSIONS: There is substantial heterogeneity in outcomes reporting among facial rejuvenation studies. Clinicians, researchers, and industry stakeholders should strive to develop a core outcome set to ensure that meaningful and consistent outcomes are reported in all clinical trials.